Athira Pharma Inc.

2.74-0.0100-0.36%Vol 2.40M1Y Perf -74.98%
Jun 24th, 2022 16:00 DELAYED
BID2.72 ASK2.74
Open2.67 Previous Close2.75
Pre-Market- After-Market2.78
 - -  0.04 1.46%
Target Price
33.50 
Analyst Rating
Strong Buy 1.00
Potential %
1.12K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
1.49 
Earnings Rating
Market Cap103.12M 
Earnings Date
15th Aug 2022
Alpha-0.04 Standard Deviation0.25
Beta3.28 

Today's Price Range

2.652.83

52W Range

2.5316.65

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-68.14%
1 Month
-69.25%
3 Months
-78.49%
6 Months
-78.94%
1 Year
-74.98%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ATHA2.74-0.0100-0.36
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.63-0.5611.11
Q04 2021-0.61-0.3739.34
Q03 2021-0.50-0.4216.00
Q02 2021-0.37-0.38-2.70
Q01 2021-0.30-0.2516.67
Q04 2020-0.29-0.2417.24
Q03 2020-0.25-1.12-348.00
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date15th Aug 2022
Estimated EPS Next Report-0.62
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume2.40M
Shares Outstanding37.64K
Shares Float33.73M
Trades Count10.55K
Dollar Volume6.66M
Avg. Volume3.01M
Avg. Weekly Volume6.84M
Avg. Monthly Volume1.48M
Avg. Quarterly Volume706.11K

Athira Pharma Inc. (NASDAQ: ATHA) stock closed at 2.74 per share at the end of the most recent trading day (a -0.36% change compared to the prior day closing price) with a volume of 2.40M shares and market capitalization of 103.12M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. Athira Pharma Inc. CEO is Leen Kawas.

The one-year performance of Athira Pharma Inc. stock is -74.98%, while year-to-date (YTD) performance is -78.97%. ATHA stock has a five-year performance of %. Its 52-week range is between 2.53 and 16.65, which gives ATHA stock a 52-week price range ratio of 1.49%

Athira Pharma Inc. currently has a PE ratio of -4.70, a price-to-book (PB) ratio of 1.02, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -19.63%, a ROC of -20.15% and a ROE of -20.13%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Athira Pharma Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.62 for the next earnings report. Athira Pharma Inc.’s next earnings report date is 15th Aug 2022.

The consensus rating of Wall Street analysts for Athira Pharma Inc. is Strong Buy (1), with a target price of $33.5, which is +1 122.63% compared to the current price. The earnings rating for Athira Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Athira Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Athira Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.15, ATR14 : 0.86, CCI20 : -223.20, Chaikin Money Flow : 0.10, MACD : -1.35, Money Flow Index : 15.51, ROC : -70.31, RSI : 15.79, STOCH (14,3) : 2.84, STOCH RSI : 0.00, UO : 21.77, Williams %R : -97.16), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Athira Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Athira Pharma Inc.

Athira Pharma Inc is a bio-technology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

CEO: Leen Kawas

Telephone: +1 206 221-8112

Address: 4000 Mason Road, Seattle 98195, WA, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

71%29%

Bearish Bullish

60%40%

TipRanks News for ATHA

Thu, 21 Apr 2022 10:05 GMT Athira Pharma (ATHA) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Fri, 25 Mar 2022 04:25 GMT Athira Pharma (ATHA) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits